Effect and safety of combination lipid-lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events

Chunli Wang | Fei Wang | Qing Cao | Zhen Li | Liya Huang | Shuyan Chen

Department of Geriatrics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence
Shuyan Chen, Department of Geriatrics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Email: chenshuyan@xinhuamed.com.cn

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81471399

Abstract
This study aimed to compare the effect and safety of statin monotherapies and combination therapies on lipid-lowering therapies. We searched for published randomized controlled trial (RCT) reports of statin monotherapies and combination therapies in patients with high risk of cardiovascular events, and extracted lipid levels to perform meta-analysis. A total of 12 RCT reports were included in this study. According to the new guidelines (low-density lipoprotein cholesterol [LDL-C] < 100 mg/dL, high-density lipoprotein cholesterol [HDL-C] > 130 mg/dL), the percent of LDL-C attaining goals in combination therapy is more than that of monotherapy (risk ratio [RR] = 1.43, 95% confidence interval [CI]: 1.13 to 1.82, \( P = 0.003 \)), and the percent of LDL-C and HDL-C attaining goals in combination therapy is greater than that of monotherapy (RR = 1.43, 95% CI: 1.24 to 1.65, \( P = 0.000 \)). The changing level of blood lipid had significant statistical difference between the two groups. The degree of blood lipid lowered by combination therapy was larger than in monotherapy (standard mean difference [SMD] = –0.45, 95% CI: –0.75 to –0.14, \( P = 0.004 \); SMD = –0.72, 95% CI: 0.04 to 1.39, \( P = 0.039 \); and SMD = –0.71, 95% CI: –1.12 to –0.3, \( P = 0.001 \) in LDL-C, HDL-C, and triglyceride, respectively). The incidence of adverse events was not significantly different between the two groups (RR = 1.15, 95% CI: 0.91 to 1.37, \( P = 0.096 \); RR = 1.5, 95% CI: 0.55 to 4.1, \( P = 0.427 \); RR = 0.63, 95% CI: 0.33 to 1.24, \( P = 0.181 \) in incidence of total adverse events, drug-related treatment, and myalgia, respectively). Combination therapy can bring better effect in reducing lipid. It does not increase the incidence of adverse events, so it can be used widely and safely.

KEYWORDS
cardiovascular events, combination therapy, lipid-lowering, statin monotherapies

1 | INTRODUCTION

Coronary heart disease (CHD) has been the main threat to people's health in recent years. While the major factor for CHD is atherosclerosis, the most relevant factor of atherosclerosis is low-density lipoprotein cholesterol (LDL-C) level. Many clinical trials have confirmed that statin treatment could lower LDL-C levels and substantially reduce the morbidity and mortality of atherosclerotic
cardiovascular disease (ASCVD). Moreover, even with high-dose statin therapies, the residual risk of major adverse cardiovascular events still exists.

Studies have indicated that many factors, such as dyslipidemia, smoking, hypertension, diabetes, metabolic disorder, and alcohol, account for most of the risk of vascular events. Dyslipidemia is the major factor among these risks. Lowering LDL-C levels by statins reduces cardiovascular events after acute coronary syndrome, while dyslipidemia is characterized by high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) levels, and an accumulation of cholesterol-rich remnant particles with high levels of apolipoprotein B. Although lowering the LDL-C level in these patients is the primary goal, in order to reduce cardiovascular risk, recent therapy guidelines have emphasized consideration of other lipoprotein abnormalities as well as non-lipid risk factors (including smoking, blood pressure, and weight management) that contribute to global risk.

There are also patients who have no response or sensitivity to monotherapy drugs, such as statins, because of their own physical fitness. Furthermore, high-dose monotherapy statins can increase the incidence of adverse drug events as well as therapy costs and they can be hard for some patients to tolerate.

This study aimed to find other lipid-lowering drugs to evaluate the effect and safety from all of the available data. Statins are hydroxymethylglutaryl coenzyme A reductase inhibitors, inhibiting the synthesis of cholesterol. Other LDL-C-lowering agents include niacin, omega-3, and fibrate. Fibrates activate the peroxisome proliferator-activated receptor α, a transcription factor that regulates the expression of a number of genes involved in multiple metabolic pathways, including lipid metabolism, ultimately reducing plasma TG concentrations and enhancing HDL levels. Fibrates have a beneficial action on the atherogenic dyslipidemia. Niacin inhibits the activity of phosphodiesterase, and reduces the synthesis of TG and the secretion of very-low-density lipoprotein; it can raise the activity of lipoprotein lipase (LPL), resulting in the hydrolysis of TG, and lowering the synthesis of apolipoprotein B. It can also enhance HDL level, lower TG level, and lower α-lipoprotein.

The differences in action mechanisms of all kinds, resulting in different pharmacological effects and an improvement of different components of the lipid profile, provide a rationale for their use in combination in patients with high residual cardiovascular risk related to atherogenic dyslipidemia and persisting after single therapy, such as patients with metabolic syndrome, type 2 diabetes, or kidney disease.

2 | MATERIALS AND METHODS

2.1 | Search strategy

We searched the major medical databases, such as PubMed, Embase, Ovid, ScienceDirect, Springer, and Web of Science, for randomized controlled trials (RCTs) comparing combination lipid-lowering therapies based on statin treatment with statin monotherapies for major cardiovascular events. We included articles published from January 2000 to April 2018, and the search terms used were: “statin monotherapies”, “combination”, “ASCVD”, “lipid-lowering therapies”, “randomized controlled trial” and so on.

2.2 | Criteria selection and data extraction

Inclusion criteria were as follows: (a) RCT study design, (b) recruited patients had ASCVD or were at high risk of ASCVD, (c) study compared statin monotherapies with combination therapy based on statin, (d) article reported the data of major adverse cardiovascular events, and (e) entire follow-up intervals were ≥6 weeks.

Data were abstracted using predefined data fields. The following data were extracted from each study: details of participant characteristics (age, sex, basic disease, and lifestyle), the number of patients in each group, duration of follow-up, baseline lipid levels (including TC, LDL-C, HDL-C, and TG), treatment and drug dosage, incidence of adverse events, and the percent of attaining goals.

2.3 | Statistical analysis

Standard mean difference (SMD) and risk ratio (RR) were used for the analysis of continuous and dichotomous variables, respectively. The chi-square test was used to evaluate heterogeneity among the studies, and I² was used to quantify the inconsistency. There were two models: the fixed effect model and the random effect model. The fixed effect model was used when the effects were deemed to be homogeneous (P > 0.1, I² < 50%); otherwise, the random effects model was used. The Z test was used to compare the overall difference. The confidence interval (CI) was established at 95%, and P values < 0.05 were considered to indicate statistical significance. Beggs’s test and Egger’s test were performed in order to evaluate the publication bias (in Beggs’s test P > 0.05 and in Egger’s test P > 0.05 and 95% CI includes 1; it is thought that there was no publication bias). Statistical analyses were performed using STATA 12.0 (meta module; StataCorp., College Station, TX, USA).

3 | RESULTS

3.1 | Characteristics of study selection

In total, 12 papers of RCTs that compared statin monotherapies with combination therapies were selected. The characteristics of each RCT are presented in Table 1. This meta-analysis included 6227 patients with ASCVD risk, 3108 of whom were given statin plus another drug therapy (including coenzyme A, ezetimibe, niacin, and fenofibrate) and 3119 of whom were given statin monotherapy.

3.2 | Effect of modifying lipid

3.2.1 | The percent of attaining goals

The US National Cholesterol Education Program released the third report of the Adult Treatment Panel, stating that patients with metabolic syndrome achieved a target LDL-C < 100 mg/dL as the primary
| Study             | Follow-up (weeks) | Patients (n) | Treatment (mg/d) | Patient characteristics |
|-------------------|-------------------|--------------|------------------|-------------------------|
|                   |                   |              |                  | Age (years) | Women (%) | Diabetes (%) | Hypertension (%) |
| Lai et al\(^{11}\) | 8                 | 118/94       | Statin + CoA 400 U/moderate-dose statin\(^{a}\) | 55.6 ± 11.6/53.6 ± 13.1 | 44.9/37.2 | 17.8/24.5 | 47.5/42.6 |
| Torimoto et al\(^{12}\) | 12               | 39/36        | Rosuvastatin 2.5 + ezetimibe/10 rosuvastatin 5 | 66.3 ± 11.7/63.0 ± 13.0 | 38.0/56.0 | 100.0/100.0 | 72.0/64.0 |
| Insull et al\(^{13}\) | 12               | 114/79       | Niacin + simvastatin/atorvastatin (40) | 55.1 ± 12.1/51.5 ± 11.1 | 62.3/48.1 | 21.1/12.7 | 48.2/36.7 |
| Weinstein et al\(^{14}\) | 16               | 140/140      | FA45 + R/R\(^{c}\) | 65.1 ± 10.5/67.4 ± 11.15 | 55.7/50.7 | 59.3/55.7 | 93.6/93.6 |
| Farnier et al\(^{15}\) | 12               | 123/125      | Fenofibrate 160 + pravastatin 40/pravastatin 40 | 57.8 ± 9.3/58.1 ± 9.3 | 30.1/29.6 | 76.0/78.0 |
| Ballantyne et al\(^{16}\) | 6                | 239/230      | Rosuvastatin 40 + ezetimibe 10/rosuvastatin 40 | 63.1 ± 10.2/63.5 ± 10.6 | 41.4/44.3 | 34.4/39.6 | 86.6/87.0 |
| Davidson et al\(^{17}\) | 12               | 73/74        | Atorvastatin 40 + fenofibrate 145/atorvastatin 40 | 54.9 ± 10.7/56.3 ± 9.88 | 45.2/52.7 | 59.3/55.7 | 93.6/93.6 |
| Tsuji et al\(^{18}\) | 36-48             | 100/102      | Atorvastatin\(^{d}\) + ezetimibe 10/atorvastatin | 66.0 ± 10.0/67.0 ± 10.0 | 22.0/22.0 | 75.0/66.0 |
| Muhlestein et al\(^{19}\) | 12               | 100/100      | Simvastatin 20 + fenofibrate 160/simvastatin 20 | 58.8/61.4 | 42.0/41.0 | 100.0/100.0 | 77.0/69.0 |
| Taylor et al\(^{20}\) | 48               | 87/80        | Simvastatin 20 + niacin 1000-1500/simvastatin 20 | 67.0 ± 10.0/68.0 ± 10.0 | 10.3/7.5 | 27.6/27.5 | 73.6/76.3 |
| AIM-HIGH Investigators et al\(^{21}\) | 144             | 1718/1696    | Niacin 1500 + simvastatin 40/simvastatin 40 | 63.7 ± 8.8/63.7 ± 8.7 | 14.7/14.8 | 34.2/33.6 | 72.8/70.1 |
| Kastelein et al\(^{22}\) | 96               | 357/363      | Simvastatin 80 + ezetimibe 10/simvastatin 80 | 46.1 ± 9.0/45.7 ± 10.0 | 47.5/50.7 | 2.2/1.4 | 18.8/14.0 |

\(^{a}\)Pitavastatin 4 mg/d, rosvastatin 10 mg/d, atorvastatin 20 mg/d, pravastatin 40 mg/d, lovastatin 40 mg/d, simvastatin 40 mg/d, or fluvastatin 80 mg/d.

\(^{b}\)Weeks 1-4, 1000/40 mg/d, Weeks 5-12, 2000/40 mg/d.

\(^{c}\)Rosuvastatin 5 mg for 8 wks, then 10 mg for 8 additional weeks.

\(^{d}\)Atorvastatin was increased by titration within the usual dose range with a treatment goal of LDL-C < 70 mg/dL on the basis of published lipoprotein management guidelines.
goal of therapy and a target non-HDL-C < 130 mg/dL as the secondary goal of therapy if elevated TG was coexisting.6 There are four studies11,12,15,16 comparing the percent of attaining LDL-C goals between two groups (Figure 1) and three studies11,15,16 comparing the percent of attaining LDL-C and non-HDL-C level goals in the meantime (Figure 2). The percent of attaining goals with combination therapy was bigger than that of monotherapy in LDL-C ($z = 2.93$, $P = 0.003$), as was that in LDL-C and non-HDL-C in the meantime ($z = 4.87$, $P = 0.000$). Begg’s test and Egger’s test both show no publication bias in LDL-C (Begg’s test: $Pr > |z| = 0.734 > 0.05$; Egger’s test: $Pr > |t| = 0.545 > 0.05$; 95% CI: $-8.056724$ to $11.30788$) or non-HDL-C (Begg’s Test: $Pr > |z| = 0.296 > 0.05$; Egger’s test: $Pr > |t| = 0.247 > 0.05$; 95% CI: $-21.23999$ to $31.37664$).

Foody et al23 found that combination ezetimibe/statin therapy improves goal attainment and reduces the use of high-potency or high-dose statins in high risk of cardiovascular disease. This is also testified in this article.

### 3.2.2 Change of lipid level

The final LDL-C level reduced more significantly from baseline in the combination group than in the statin monotherapy group (Figure 3). Data collected from 10 studies11-15,17,18,20-22 show a greater change level in combination therapy ($z = 2.80$, $P = 0.005$). The final HDL-C level in the combination group increased more from baseline than that in statin monotherapy (Figure 4). Data collected from 10 studies11-15,17,18,20-22 show a greater change level in combination therapy ($z = 17.62$, $P = 0.000$). The final TG level in the combination group reduced less from baseline than that in statin monotherapy (Figure 5). Data collected from six studies11,12,14,15,17,20 show a greater change level in combination therapy ($z = 3.41$, $P = 0.001$).

LDL-C response is typically dependent on baseline LDL-C and inversely related to baseline TG. Many studies proved that the reduction of LDL-C was remarkable with combination therapy.24-26

### 3.2.3 Adverse events

Four trials13-15,17 reported the incidence of drug-related adverse events (Figure 6) and four trials13,14,16,17 reported the incidence of myalgia (Figure 7). Compared with statin monotherapy, there was no difference with statin combination therapy in the incidence of drug-related adverse events ($z = 0.79$, $P = 0.427$; Begg’s test: $Pr > |z| = 1.000$). There was also no difference between statin combination therapy and statin monotherapy in the incidence of myalgia ($z = 1.34$, $P = 0.181$). Combination therapy does not reduce the incidence of adverse events.
FIGURE 3  The changed level of LDL-C

| Study                     | SMD (95% CI)         | %     |
|---------------------------|----------------------|-------|
| Lai et al                  | 0.01 (−0.26, 0.28)   | 10.01 |
| Torimoto et al             | −0.11 (−0.57, 0.34)  | 7.85  |
| Insull et al               | 0.87 (0.57, 1.17)    | 9.68  |
| Weinstein et al            | 0.21 (−0.02, 0.45)   | 10.41 |
| Farnier et al              | 0.23 (−0.02, 0.48)   | 10.25 |
| Davidson et al             | 0.31 (−0.01, 0.64)   | 9.38  |
| Tsuji et al                | 0.11 (−0.17, 0.39)   | 9.96  |
| Taylor et al               | 0.70 (0.39, 1.01)    | 9.53  |
| AIM-HIGH Investigators et al| 0.65 (0.58, 0.72)    | 11.69 |
| Kastelein et al            | 0.07 (−0.08, 0.21)   | 11.23 |
| Overall (I² = 90.8%, P = 0.000) | 0.31 (0.09, 0.53)    | 100.00|

NOTE: Weights are from random effects analysis

FIGURE 4  The changed level of HDL-C

| Study                     | SMD (95% CI)         | %     |
|---------------------------|----------------------|-------|
| Lai et al                  | −0.30 (−0.57, −0.02) | 10.05 |
| Torimoto et al             | −1.32 (−1.83, −0.82) | 7.59  |
| Insull et al               | 0.14 (−0.15, 0.42)   | 9.90  |
| Weinstein et al            | −0.26 (−0.50, −0.03) | 10.41 |
| Farnier et al              | −0.55 (−0.81, −0.30) | 10.23 |
| Davidson et al             | 0.10 (−0.22, 0.42)   | 9.52  |
| Tsuji et al                | −0.46 (−0.74, −0.18) | 9.98  |
| Taylor et al               | 0.14 (−0.16, 0.44)   | 9.73  |
| AIM-HIGH Investigators et al| −0.15 (−0.22, −0.08) | 11.51 |
| Kastelein et al            | −0.85 (−1.01, −0.70) | 11.08 |
| Overall (I² = 91.9%, P = 0.000) | −0.34 (−0.57, −0.10) | 100.00|

NOTE: Weights are from random effects analysis
Neither Begg’s test nor Egger’s test show a publication bias (Egger’s test $Pr > |z| = 0.954, 95\% CI: -341.665$ to $345.6016$) in the incidence of drug-related adverse events or in the incidence of myalgia (Begg’s test $Pr > |z| = 1.000, Pr > |t| = 0.403, 95\% CI: -35.44793$ to $28.58507$).

**DISCUSSION**

Residual cardiovascular risk persists despite of the achievement of target LDL-C levels with statin monotherapy for some high-risk cardiovascular patients. It is well accepted that residual cardiovascular...
risk is partially due to low HDL-C and high TG. Therefore, raising HDL-C and lowering TG represent an important strategy for reducing residual cardiovascular risk in patients already treated with statins. There are other people who cannot tolerate a high dose of statin. With the increase of statin dosage, the incident of adverse events reportedly increases; thus, a drug to effectively replace statin is needed.

Ezetimibe primarily reduces LDL-C levels (19%), with more modest reductions in TG (8%) and increases in HDL-C (3%) in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. Niacin primarily increases HDL-C levels (15%-35%), and to a lesser extent reduces triglycerides (20%-50%), with moderate LDL-C-lowering effects (5%-25%). Omega-3 fatty acids are effective agents for lowering TG. The GISSI-Prevenzione trial showed that dietary supplementation with omega-3 fatty acids reduced mortality by 20% in survivors of myocardial infarction. The percent reductions in LDL-C level in ezetimibe/rosuvastatin combination groups were more than 50% from baseline.

The addition of niacin, omega-3 fatty acids, or fibrates to statin therapy has produced their expected additive lipid effects but has failed to achieve a clinical benefit. Adding ezetimibe to statin therapy can further lower LDL-C safely and translate into a clinical benefit in patients at high risk of cardiovascular events.

Adding fenofibrinic acid had a modest, incremental, favorable effect on LDL-C, non-HDL-C, total cholesterol, and hypersensitive C-reactive protein between moderate- and low-dose combination therapy, and the effect on TG and HDL-C was similar whether fenofibrinic acid was combined with a moderate- or low-dose statin. This was expected as only the statin dose was increased. Higher-dose combination therapy does not provide additional benefits on TG and HDL-C.

There is no need to increase the dose of statin if statin monotherapy fails to attain the treatment goals, and a moderate dose should suffice. High-dose statin generates the same effect with the moderate dose, but increases the incidence of adverse events. Additional appropriate lipid-modified drug combination therapy can be used according to the patient’s blood lipid level. Combination therapy can lower LDL-C and TG and increase HDL-C more effectively, but will not reduce the risk of adverse cardiovascular events. Thus, in a clinical context, this treatment must be selected carefully.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (81471399).

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest to disclose.

AUTHOR CONTRIBUTIONS
C.W., F.W., and S.C. designed the study; C.W. and F.W. carried out the cell experiments; Q.C., Z.L., and L.H. provided the facilities for experiments and made suggestions on the performance of experiments. All authors have read and approved the final manuscript.
REFERENCES
1. Baireid C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
2. Afifal AO, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93:914-921.
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
4. Nosaka K, Miyoshi T, Iwamoto M, et al. Early initiation of eicosapentanoic acid and statin therapy is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. Int J Cardiol. 2017;228:173-179.
5. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89:2601-2607.
6. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol. 2006;21:400-404.
7. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
8. Meikle PJ, Wong G, Tan R, et al. Statin action favours normalisation of the plasma lipidome in the atherogenic mixed dyslipidemia of metabolic syndrome: potential relevance to statin metabolism. J Lipid Res. 2015;56:2381-2392.
9. Roussel R, Chaingnot C, Weill A, et al. Use of fibrates monotherapy in people with diabetes and high cardiovascular risk in primary care: a French nationwide cohort study based on national administrative databases. PLoS ONE. 2015;10:e0137733.
10. Xenoulis PG, Steiner JM. Canine hyperlipidaemia. J Small Anim Pract. 2015;56:595-605.
11. Lai J, Wu B, Xuan T, Xia S, Liu Z, Chen J. Efficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia. J Clin Med Res. 2015;7:446-452.
12. Torimoto K, Okada Y, Mori H, et al. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013;12:137.
13. Insull W Jr, Basile JN, Vo AN, Jiang P, Thakkar R, Padley RJ. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME Study. J Clin Lipidol. 2009;3:109-118.
14. Weinstein DL, Williams LA, Carlson DM, et al. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. Clin Ther. 2013;35:1186-1198.
15. Farnier M, Ducouj B, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am J Cardiol. 2010;106:787-792.
16. Ballantyne CM, Weiss R, Moczetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99:673-680.
17. Davidson MH, Rooney MW, Drucker J, Eugene H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009;31:2824-2838.
18. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. Am Coll Cardiol. 2015;66:495-507.
19. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2004;48:396-401.
20. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
21. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
22. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
23. Foody JM, Toth PP, Tomassini JE, et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag. 2013;9:719.
24. Farnier M, Steinmetz A, Retterstål K, Császár A. Fixed-dose combination fenofibrate/pretavastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: A double-blind, randomized comparative study. Clin Ther. 2011;33:1-12.
25. Friedman HS, Rajagopalan S, Barnes JP, Roseman H. Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Clin Ther. 2011;33:212-224.
26. Jones PH, Davidson MH, Goldberg AC, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidol. 2009;3:125-137.
27. Hong SJ, Jeong HS, Ahn JC, et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clin Ther. 2018;40:226-241.
28. Uemura Y, Watara M, Ishii H, et al. Atorvastatin 10 mg plus ezetimibe 10 mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012;59:50-56.
29. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in
combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. *Am J Cardiol*. 2003;91:1304-1310.

30. Van JT, Pan J, Wasty T, Chan E, Wu X, Charles MA. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. *Am J Cardiol*. 2002;89:1306-1308.

31. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med*. 2012;367:309-318.

32. Ip C-K, Jin D-M, Gao J-J, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials. *Int J Cardiol*. 2015;191:138-148.

33. Trialists CT. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267-1278.